Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-12-04T19:34:44.807Z Has data issue: false hasContentIssue false
  • English
  • Français

Antiprogestin Drugs: Research and Clinical Use in Sweden

Published online by Cambridge University Press:  29 April 2021

Marc Bygdeman  and
Marja-Liisa Swahn
Get access Rights & Permissions [Opens in a new window]

Extract

Progesterone is essential both for ovulation and for the formation of the secretory endometrium which is required for nidation: it plays a central role in the establishment and maintenance of pregnancy. Given the multifaceted role of progesterone in the reproductive process, an anti-progestational compound such as RU 486 (Mifepristone, Roussel-Uclaf, Paris, France) could be expected to have a number of potential clinical applications in human fertility regulation including termination of pregnancy, induction of missed menses, postcoital contraception and inhibition of ovulation and implantation.

Our research and clinical evaluation have mainly been directed to termination of pregnancy and to inhibition of implantation. The aim of this presentation is to summarize briefly our experience with the use of RU 486 in these areas.

Type
Medical and Health Services Issues
Information
Law, Medicine and Healthcare , Volume 20 , Issue 3 , Fall 1992 , pp. 157 - 160
Copyright
© 1992 American Society of Law, Medicine & Ethics

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kovacs, L., Sas, M., Resh, B.A., Ugocsai, G., Swahn, M.L., Bygdeman, M. and Rowe, P.J., “Termination of Early Pregnancy by RU 486—An Antiprogestational Compound”, Contraception, 29 (1984), pp. 399–410.CrossRefGoogle Scholar
Bygdeman, M. and Swahn, M.L., “Progesterone Receptor Blockage. Effect on Uterine Contractility and Early Pregnancy”, Contraception, 32 (1985), pp. 45–51; Swahn, M.L. and Bygdeman, M., “The Effect of the Antiprogestin RU 486 on Uterine Contractility and Sensitivity to Prostaglandin and Oxytocin”, British Journal of Obstetrics and Gynaecology, 95 (1988), pp. 126–34.CrossRefGoogle Scholar
Swahn, M.L. and Bygdeman, M., “Termination of Early Pregnancy with RU 486 (Mifepristone) in Combination with a Prostaglandin Analogue (Sulprostone)”, Acta Obstetricia et Gynecologica Scandinavica, 68 (1989), pp. 293–300.10.3109/00016348909028661CrossRefGoogle Scholar
Holmgren, K., “Women's Evaluation of Three Early Abortion Methods”, Acta Obstetricia et Gynecologica Scandinavica, (submitted).Google Scholar
Holmgren, K., “Time of Decision to Undergo a Legal Abortion”, Gynecologic and Obstetric Investigation, 26 (1988), pp. 289–95.Google Scholar
Ibid.Google Scholar
Gottlieb, C. and Bygdeman, M., “The Use of Antiprogestin (RU 486) for Termination of Second Trimester Pregnancy”, Acta Obstetricia et Gynecologica Scandinavica, 70 (1991), pp. 199–203; Gottlieb, C. and Bygdeman, M., “Antiprogestin and Prostaglandins for Termination of Mid- and Late Second Trimester Pregnancy,” (to be published).10.3109/00016349109006210CrossRefGoogle Scholar
Rådestad, A., Christensen, N.J. and Strömberg, L., “Induced Cervical Ripening with Mifepristone in First Trimester Pregnancy. A Double Blind Randomized Biomechanical Study”, Contraception, 38 (1988), pp. 301–12.CrossRefGoogle Scholar
Swahn, M.L., Johannisson, E., Daniore, V., de la Torre, B. and Bygdeman, M., “The Effect of RU 486 Administered During the Proliferative and Secretory Phase of the Cycle on the Bleeding Pattern, Hormonal Parameters and the Endometrium”, Human Reproduction, 3 (1988), pp. 915–21.CrossRefGoogle Scholar
Swahn, M.L., Bygdeman, M., Xing, S., Cekan, S., Masironi, B. and Johannisson, E., “The Effect of RU 486 Administered During the Early Luteal Phase on Bleeding Pattern, Hormonal Parameters and Endometrium”, Human Reproduction, 42 (1990), pp. 402–8.10.1093/oxfordjournals.humrep.a137111CrossRefGoogle Scholar
Gemzell, K., Swahn, M.L. and Bygdeman, M., “Regulation of Non-Pregnant Human Uterine Contractility: Effects of Anti-hormones”, Contraception, 42 (1990), pp. 323–35.10.1016/0010-7824(90)90020-VCrossRefGoogle Scholar
Swahn, M.L., Bygdeman, M., Seppälä, M., Johannisson, E. and Cekan, S., “Effect of Tamoxifen Alone and in Combination with RU 486 on the Endometrium at the Time of Implantation”, Human Reproduction, (submitted); Mäentausta, O., Gemzell, K., Svalander, P., Bygdeman, M. and Vihko, R. “The Effects of an Antiprogestin, Mifepristone, and an Antiestrogen, Tamoxifen, on the Endometrial 17b-Hydroxy-Steroid-Dehydrogenase and Progesterone and Estrogen Receptors During the Luteal Phase of the Menstrual Cycle: An Immunohistochemical Study,”(to be published).Google Scholar
Navot, D., Scott, R.T., Droesch, K., Veeck, L.L., Liw, H.C. and Rosenwakz, L., “The Window of Embryo Transfer and the Efficiency of Human Contraception in vitro”, Fertility and Sterility, 55 (1991), pp. 114–8.CrossRefGoogle Scholar
Swahn, M.L., Gemzell, K. and Bygdeman, M., “Contraception with Mifepristone”, Lancet, 338 (1991), pp. 942–3.CrossRefGoogle Scholar